Engineered T Cells Market by Type (Chimeric Antigen Receptor (Car) Modified T Cells, T Cells Receptor (Tcr) Modified T Cells and Tumor Infiltrating Lymphocytes), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others Application), and End User (Hospital, Cancer Research Center, and Clinic): Global Opportunity Analysis and Industry Forecast, 2021––2030
The global engineered T cells market was valued at $9,668.0 million in 2020, and is projected to reach $149,650.6 million by 2030, registering a CAGR of 32.5% from 2021 to 2030.
T cell is a type of white blood cell, which plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient’s body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells.
The increase in prevalence of cancer globally drives the growth of engineered T cells market. For instance, according to World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In addition, surge in geriatric population propels the growth of engineered T cells market. The R&D in the T cell technology by manufacturers and researchers contributes in the growth of market. Furthermore, initiatives taken by governments and private organization to treat and improve the lifestyle of cancer patients boost the market growth. The rise in number of hospitals and well-developed healthcare infrastructure further contributes in market growth.
In addition, increase in advancement in T cell therapy and new product launch contribute in the growth of the engineered T cells market. However, the high cost of T cell technology is expected to limit the growth of market.
The engineered T cells market is segmented on the basis of type, application, end user, and region. By type, the market is mainly categorized into chimeric antigen receptor (CAR) modified T cells, T cells receptor (TCR) modified T cells, and tumor infiltrating lymphocytes. By application, it is categorized into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia and others application. Based on end user, it is divided into hospital, cancer research center, and clinic. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Amgen Inc, Athenex Inc, Bellicum Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly And Company, Gilead Sciences, Inc., Novartis Ag, Oxford Biomedica Plc, Pfizer Inc., and Precision Biosciences Inc.
KEY BENEFITS FOR STAKEHOLDERS
The report provides an in-depth analysis of the global Engineered T cells market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Engineered T cells market growth.
KEY MARKET SEGMENTS
By type
Chimeric Antigen Receptor (Car) Modified T Cells
T Cells Receptor (Tcr) Modified T Cells
Tumor Infiltrating Lymphocytes
By application
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Leukemia
Others Application
By end user
Hospitals
Cancer Research Centers
Clinics
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
Amgen Inc
Athenex Inc
Bellicum Pharmaceuticals, Inc.
Bristol-Myers Squibb
Eli Lilly And Company
Gilead Sciences, Inc.
Novartis Ag
Oxford Biomedica Plc
Pfizer Inc.
Precision Biosciences Inc.
- CHAPTER 1:INTRODUCTION
- 1.1.Report Description
- 1.2.Key Market Segments
- 1.3.Key Benefits
- 1.4.Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.CXO Perspective
- CHAPTER 3:MARKET LANDSCAPE
- 3.1.Market Definition and Scope
- 3.2.Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3.Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4.Market Share Analysis/Top Player Positioning
- 3.4.1. Market Share Analysis/Top Player Positioning 2020
- 3.5.Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities
- 3.6.COVID-19 Impact Analysis
- CHAPTER 4:ENGINEERED T CELLS MARKET, BY TYPE
- 4.1.Market Overview
- 4.1.1Market Size and Forecast, By Type
- 4.2. Chimeric Antigen Receptor (CAR) Modified T Cells
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. T Cells Receptor (TCR) Modified T Cells
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Tumor Infiltrating Lymphocytes
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- CHAPTER 5:ENGINEERED T CELLS MARKET, BY APPLICATION
- 5.1.Market Overview
- 5.1.1Market Size and Forecast, By Application
- 5.2. Lung Cancer
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Breast Cancer
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Colorectal Cancer
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- 5.5. Melanoma
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country
- 5.6. Leukemia
- 5.6.1. Key Market Trends, Growth Factors and Opportunities
- 5.6.2. Market Size and Forecast, By Region
- 5.6.3. Market Share Analysis, By Country
- 5.7. Others Application
- 5.7.1. Key Market Trends, Growth Factors and Opportunities
- 5.7.2. Market Size and Forecast, By Region
- 5.7.3. Market Share Analysis, By Country
- CHAPTER 6:ENGINEERED T CELLS MARKET, BY END USER
- 6.1.Market Overview
- 6.1.1Market Size and Forecast, By End User
- 6.2. Hospitals
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Cancer Research Centers
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Clinics
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7:ENGINEERED T CELLS MARKET, BY REGION
- 7.1.Market Overview
- 7.1.1Market Size and Forecast, By Region
- 7.2.North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. United States Engineered T Cells Market
- 7.2.6.1. Market Size and Forecast, By Type
- 7.2.6.2. Market Size and Forecast, By Application
- 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Engineered T Cells Market
- 7.2.7.1. Market Size and Forecast, By Type
- 7.2.7.2. Market Size and Forecast, By Application
- 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Engineered T Cells Market
- 7.2.8.1. Market Size and Forecast, By Type
- 7.2.8.2. Market Size and Forecast, By Application
- 7.2.8.3. Market Size and Forecast, By End User
- 7.3.Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Engineered T Cells Market
- 7.3.6.1. Market Size and Forecast, By Type
- 7.3.6.2. Market Size and Forecast, By Application
- 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. Germany Engineered T Cells Market
- 7.3.7.1. Market Size and Forecast, By Type
- 7.3.7.2. Market Size and Forecast, By Application
- 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. Italy Engineered T Cells Market
- 7.3.8.1. Market Size and Forecast, By Type
- 7.3.8.2. Market Size and Forecast, By Application
- 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Spain Engineered T Cells Market
- 7.3.9.1. Market Size and Forecast, By Type
- 7.3.9.2. Market Size and Forecast, By Application
- 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. U.K Engineered T Cells Market
- 7.3.10.1. Market Size and Forecast, By Type
- 7.3.10.2. Market Size and Forecast, By Application
- 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest Of Europe Engineered T Cells Market
- 7.3.11.1. Market Size and Forecast, By Type
- 7.3.11.2. Market Size and Forecast, By Application
- 7.3.11.3. Market Size and Forecast, By End User
- 7.4.Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Engineered T Cells Market
- 7.4.6.1. Market Size and Forecast, By Type
- 7.4.6.2. Market Size and Forecast, By Application
- 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. Japan Engineered T Cells Market
- 7.4.7.1. Market Size and Forecast, By Type
- 7.4.7.2. Market Size and Forecast, By Application
- 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. India Engineered T Cells Market
- 7.4.8.1. Market Size and Forecast, By Type
- 7.4.8.2. Market Size and Forecast, By Application
- 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. South Korea Engineered T Cells Market
- 7.4.9.1. Market Size and Forecast, By Type
- 7.4.9.2. Market Size and Forecast, By Application
- 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. Australia Engineered T Cells Market
- 7.4.10.1. Market Size and Forecast, By Type
- 7.4.10.2. Market Size and Forecast, By Application
- 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia Pacific Engineered T Cells Market
- 7.4.11.1. Market Size and Forecast, By Type
- 7.4.11.2. Market Size and Forecast, By Application
- 7.4.11.3. Market Size and Forecast, By End User
- 7.5.LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Engineered T Cells Market
- 7.5.6.1. Market Size and Forecast, By Type
- 7.5.6.2. Market Size and Forecast, By Application
- 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. South Africa, Engineered T Cells Market
- 7.5.7.1. Market Size and Forecast, By Type
- 7.5.7.2. Market Size and Forecast, By Application
- 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. Saudi Arabia Engineered T Cells Market
- 7.5.8.1. Market Size and Forecast, By Type
- 7.5.8.2. Market Size and Forecast, By Application
- 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Engineered T Cells Market
- 7.5.9.1. Market Size and Forecast, By Type
- 7.5.9.2. Market Size and Forecast, By Application
- 7.5.9.3. Market Size and Forecast, By End User
- CHAPTER 8:COMPANY PROFILES
- 8.1. Amgen Inc.
- 8.1.1.Company Overview
- 8.1.2.Key Executives
- 8.1.3.Company snapshot
- 8.1.4.Operating business segments
- 8.1.5.Product portfolio
- 8.1.6.Business Performance
- 8.1.7.Key Strategic Moves and Developments
- 8.2. Athenex, Inc.
- 8.2.1.Company Overview
- 8.2.2.Key Executives
- 8.2.3.Company snapshot
- 8.2.4.Operating business segments
- 8.2.5.Product portfolio
- 8.2.6.Business Performance
- 8.2.7.Key Strategic Moves and Developments
- 8.3. Bellicum Pharmaceuticals Inc
- 8.3.1.Company Overview
- 8.3.2.Key Executives
- 8.3.3.Company snapshot
- 8.3.4.Operating business segments
- 8.3.5.Product portfolio
- 8.3.6.Business Performance
- 8.3.7.Key Strategic Moves and Developments
- 8.4. Bristol-Myers Squibb
- 8.4.1.Company Overview
- 8.4.2.Key Executives
- 8.4.3.Company snapshot
- 8.4.4.Operating business segments
- 8.4.5.Product portfolio
- 8.4.6.Business Performance
- 8.4.7.Key Strategic Moves and Developments
- 8.5. Eli Lilly And Co.
- 8.5.1.Company Overview
- 8.5.2.Key Executives
- 8.5.3.Company snapshot
- 8.5.4.Operating business segments
- 8.5.5.Product portfolio
- 8.5.6.Business Performance
- 8.5.7.Key Strategic Moves and Developments
- 8.6. Gilead Sciences, Inc.
- 8.6.1.Company Overview
- 8.6.2.Key Executives
- 8.6.3.Company snapshot
- 8.6.4.Operating business segments
- 8.6.5.Product portfolio
- 8.6.6.Business Performance
- 8.6.7.Key Strategic Moves and Developments
- 8.7. Novartis AG
- 8.7.1.Company Overview
- 8.7.2.Key Executives
- 8.7.3.Company snapshot
- 8.7.4.Operating business segments
- 8.7.5.Product portfolio
- 8.7.6.Business Performance
- 8.7.7.Key Strategic Moves and Developments
- 8.8. Oxford Biomedica
- 8.8.1.Company Overview
- 8.8.2.Key Executives
- 8.8.3.Company snapshot
- 8.8.4.Operating business segments
- 8.8.5.Product portfolio
- 8.8.6.Business Performance
- 8.8.7.Key Strategic Moves and Developments
- 8.9. Pfizer Inc.
- 8.9.1.Company Overview
- 8.9.2.Key Executives
- 8.9.3.Company snapshot
- 8.9.4.Operating business segments
- 8.9.5.Product portfolio
- 8.9.6.Business Performance
- 8.9.7.Key Strategic Moves and Developments
- 8.10. Precision BioSciences, Inc.
- 8.10.1.Company Overview
- 8.10.2.Key Executives
- 8.10.3.Company snapshot
- 8.10.4.Operating business segments
- 8.10.5.Product portfolio
- 8.10.6.Business Performance
- 8.10.7.Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL ENGINEERED T CELLS MARKET, BY TYPE, 2020-2030 ($MILLION)
- TABLE 2. GLOBAL ENGINEERED T CELLS MARKET FOR CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS, BY REGION, 2020-2030 ($MILLION)
- TABLE 3. GLOBAL ENGINEERED T CELLS MARKET FOR T CELLS RECEPTOR (TCR) MODIFIED T CELLS, BY REGION, 2020-2030 ($MILLION)
- TABLE 4. GLOBAL ENGINEERED T CELLS MARKET FOR TUMOR INFILTRATING LYMPHOCYTES, BY REGION, 2020-2030 ($MILLION)
- TABLE 5. GLOBAL ENGINEERED T CELLS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 6. GLOBAL ENGINEERED T CELLS MARKET FOR LUNG CANCER, BY REGION, 2020-2030 ($MILLION)
- TABLE 7. GLOBAL ENGINEERED T CELLS MARKET FOR BREAST CANCER, BY REGION, 2020-2030 ($MILLION)
- TABLE 8. GLOBAL ENGINEERED T CELLS MARKET FOR COLORECTAL CANCER, BY REGION, 2020-2030 ($MILLION)
- TABLE 9. GLOBAL ENGINEERED T CELLS MARKET FOR MELANOMA, BY REGION, 2020-2030 ($MILLION)
- TABLE 10. GLOBAL ENGINEERED T CELLS MARKET FOR LEUKEMIA, BY REGION, 2020-2030 ($MILLION)
- TABLE 11. GLOBAL ENGINEERED T CELLS MARKET FOR OTHERS APPLICATION, BY REGION, 2020-2030 ($MILLION)
- TABLE 12. GLOBAL ENGINEERED T CELLS MARKET, BY END USER, 2020-2030 ($MILLION)
- TABLE 13. GLOBAL ENGINEERED T CELLS MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
- TABLE 14. GLOBAL ENGINEERED T CELLS MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 2020-2030 ($MILLION)
- TABLE 15. GLOBAL ENGINEERED T CELLS MARKET FOR CLINICS, BY REGION, 2020-2030 ($MILLION)
- TABLE 16. GLOBAL ENGINEERED T CELLS MARKET, BY REGION, 2020-2030 ($MILLION)
- TABLE 17. NORTH AMERICA ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 18. NORTH AMERICA ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 19. NORTH AMERICA ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 20. UNITED STATES ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 21. UNITED STATES ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 22. UNITED STATES ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 23. CANADA ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 24. CANADA ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 25. CANADA ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 26. MEXICO ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 27. MEXICO ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 28. MEXICO ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 29. EUROPE ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 30. EUROPE ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 31. EUROPE ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 32. FRANCE ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 33. FRANCE ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 34. FRANCE ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 35. GERMANY ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 36. GERMANY ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 37. GERMANY ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 38. ITALY ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 39. ITALY ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 40. ITALY ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 41. SPAIN ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 42. SPAIN ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 43. SPAIN ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 44. UNITED KINGDOM ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 45. UNITED KINGDOM ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 46. UNITED KINGDOM ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 47. REST OF EUROPE ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 48. REST OF EUROPE ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 49. REST OF EUROPE ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 50. ASIA-PACIFIC ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 51. ASIA-PACIFIC ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 52. ASIA-PACIFIC ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 53. CHINA ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 54. CHINA ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 55. CHINA ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 56. JAPAN ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 57. JAPAN ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 58. JAPAN ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 59. INDIA ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 60. INDIA ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 61. INDIA ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 62. SOUTH KOREA ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 63. SOUTH KOREA ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 64. SOUTH KOREA ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 65. AUSTRALIA ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 66. AUSTRALIA ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 67. AUSTRALIA ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 68. REST OF ASIA PACIFIC ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 69. REST OF ASIA PACIFIC ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 70. REST OF ASIA PACIFIC ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 71. LAMEA ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 72. LAMEA ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 73. LAMEA ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 74. BRAZIL ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 75. BRAZIL ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 76. BRAZIL ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 77. SOUTH AFRICA, ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 78. SOUTH AFRICA, ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 79. SOUTH AFRICA, ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 80. SAUDI ARABIA ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 81. SAUDI ARABIA ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 82. SAUDI ARABIA ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 83. REST OF LAMEA ENGINEERED T CELLS, BY TYPE, 2020-2030 ($MILLION)
- TABLE 84. REST OF LAMEA ENGINEERED T CELLS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 85. REST OF LAMEA ENGINEERED T CELLS, BY END USER, 2020-2030 ($MILLION)
- TABLE 86. AMGEN INC.: KEY EXECUTIVES
- TABLE 87. AMGEN INC.: COMPANY SNAPSHOT
- TABLE 88. AMGEN INC.: OPERATING SEGMENTS
- TABLE 89. AMGEN INC.: PRODUCT PORTFOLIO
- TABLE 90. AMGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 91. ATHENEX, INC.: KEY EXECUTIVES
- TABLE 92. ATHENEX, INC.: COMPANY SNAPSHOT
- TABLE 93. ATHENEX, INC.: OPERATING SEGMENTS
- TABLE 94. ATHENEX, INC.: PRODUCT PORTFOLIO
- TABLE 95. ATHENEX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 96. BELLICUM PHARMACEUTICALS INC: KEY EXECUTIVES
- TABLE 97. BELLICUM PHARMACEUTICALS INC: COMPANY SNAPSHOT
- TABLE 98. BELLICUM PHARMACEUTICALS INC: OPERATING SEGMENTS
- TABLE 99. BELLICUM PHARMACEUTICALS INC: PRODUCT PORTFOLIO
- TABLE 100. BELLICUM PHARMACEUTICALS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 101. BRISTOL-MYERS SQUIBB: KEY EXECUTIVES
- TABLE 102. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
- TABLE 103. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
- TABLE 104. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
- TABLE 105. BRISTOL-MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 106. ELI LILLY AND CO.: KEY EXECUTIVES
- TABLE 107. ELI LILLY AND CO.: COMPANY SNAPSHOT
- TABLE 108. ELI LILLY AND CO.: OPERATING SEGMENTS
- TABLE 109. ELI LILLY AND CO.: PRODUCT PORTFOLIO
- TABLE 110. ELI LILLY AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 111. GILEAD SCIENCES, INC.: KEY EXECUTIVES
- TABLE 112. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 113. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
- TABLE 114. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 115. GILEAD SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 116. NOVARTIS AG: KEY EXECUTIVES
- TABLE 117. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 118. NOVARTIS AG: OPERATING SEGMENTS
- TABLE 119. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 120. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 121. OXFORD BIOMEDICA: KEY EXECUTIVES
- TABLE 122. OXFORD BIOMEDICA: COMPANY SNAPSHOT
- TABLE 123. OXFORD BIOMEDICA: OPERATING SEGMENTS
- TABLE 124. OXFORD BIOMEDICA: PRODUCT PORTFOLIO
- TABLE 125. OXFORD BIOMEDICA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 126. PFIZER INC.: KEY EXECUTIVES
- TABLE 127. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 128. PFIZER INC.: OPERATING SEGMENTS
- TABLE 129. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 130. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 131. PRECISION BIOSCIENCES, INC.: KEY EXECUTIVES
- TABLE 132. PRECISION BIOSCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 133. PRECISION BIOSCIENCES, INC.: OPERATING SEGMENTS
- TABLE 134. PRECISION BIOSCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 135. PRECISION BIOSCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL ENGINEERED T CELLS MARKET SEGMENTATION
- FIGURE 2. GLOBAL ENGINEERED T CELLS MARKET
- FIGURE 3. SEGMENTATION ENGINEERED T CELLS MARKET
- FIGURE 4. TOP INVESTMENT POCKET IN ENGINEERED T CELLS MARKET
- FIGURE 5. TOP WINNING STRATEGIES, 2019-2021*
- FIGURE 6. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
- FIGURE 7. TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
- FIGURE 8. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 9. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 10. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 11. LOW THREAT OF SUBSTITUTION
- FIGURE 12. HIGH COMPETITIVE RIVALRY
- FIGURE 13. TOP PLAYER POSITIONING, 2020
- FIGURE 14. MARKET SHARE ANALYSIS, 2020
- FIGURE 15. RESTRAINTS AND DRIVERS: ENGINEERED T CELLS MARKET
- FIGURE 16. ENGINEERED T CELLS MARKET SEGMENTATION, BY TYPE
- FIGURE 17. ENGINEERED T CELLS MARKET FOR CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 18. ENGINEERED T CELLS MARKET FOR T CELLS RECEPTOR (TCR) MODIFIED T CELLS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 19. ENGINEERED T CELLS MARKET FOR TUMOR INFILTRATING LYMPHOCYTES, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 20. ENGINEERED T CELLS MARKET SEGMENTATION, BY APPLICATION
- FIGURE 21. ENGINEERED T CELLS MARKET FOR LUNG CANCER, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 22. ENGINEERED T CELLS MARKET FOR BREAST CANCER, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 23. ENGINEERED T CELLS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 24. ENGINEERED T CELLS MARKET FOR MELANOMA, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 25. ENGINEERED T CELLS MARKET FOR LEUKEMIA, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 26. ENGINEERED T CELLS MARKET FOR OTHERS APPLICATION, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 27. ENGINEERED T CELLS MARKET SEGMENTATION, BY END USER
- FIGURE 28. ENGINEERED T CELLS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 29. ENGINEERED T CELLS MARKET FOR CANCER RESEARCH CENTERS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 30. ENGINEERED T CELLS MARKET FOR CLINICS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 31. AMGEN INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 32. AMGEN INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 33. AMGEN INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 34. ATHENEX, INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 35. ATHENEX, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 36. ATHENEX, INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 37. BELLICUM PHARMACEUTICALS INC: NET SALES, 2018-2020 ($MILLION)
- FIGURE 38. BELLICUM PHARMACEUTICALS INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 39. BELLICUM PHARMACEUTICALS INC: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 40. BRISTOL-MYERS SQUIBB: NET SALES, 2018-2020 ($MILLION)
- FIGURE 41. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 42. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 43. ELI LILLY AND CO.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 44. ELI LILLY AND CO.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 45. ELI LILLY AND CO.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 46. GILEAD SCIENCES, INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 47. GILEAD SCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 48. GILEAD SCIENCES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 49. NOVARTIS AG: NET SALES, 2018-2020 ($MILLION)
- FIGURE 50. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 51. NOVARTIS AG: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 52. OXFORD BIOMEDICA: NET SALES, 2018-2020 ($MILLION)
- FIGURE 53. OXFORD BIOMEDICA: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 54. OXFORD BIOMEDICA: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 55. PFIZER INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 56. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 57. PFIZER INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 58. PRECISION BIOSCIENCES, INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 59. PRECISION BIOSCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 60. PRECISION BIOSCIENCES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook